Superworth

Royalty Pharma profit margin RPRX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
32.1%
Operating margin, 12 months
59.6%
Net margin on a year earlier
−12.3 pts
Peer median
14.5%

Over the twelve months to Jun 30, 2026, Royalty Pharma kept 32.1% of its revenue as net profit, with an operating margin of 59.6%.

Five years earlier its net margin was 43.4%.

The median for 10 healthcare stocks of a similar size is 14.5%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY202532.5%65.6%
FY202437.9%57.1%
FY202348.2%63.4%
FY20221.9%13.7%
FY202127.1%62.5%
FY202045.9%75.2%
FY2019n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2632.1%−12.3 pts59.6%
Q1 FY2634.0%−14.3 pts65.1%
Q4 FY2532.5%−5.4 pts65.6%
Q3 FY2532.7%−17.9 pts65.2%
Q2 FY2544.4%+14.3 pts79.8%
Q1 FY2548.3%+12.6 pts83.9%
Q4 FY2437.9%−10.2 pts57.1%
Q3 FY2450.5%+42.6 pts68.1%
Q2 FY2430.1%+19.3 pts42.9%
Q1 FY2435.7%+21.6 pts42.0%
Q4 FY2348.2%+46.3 pts63.4%
Q3 FY237.9%−14.6 pts17.1%

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyProfit margin
RPRXRoyalty Pharma32.1%
RMDResMed26.9%
BIIBBiogen8.3%
CNCCentene−2.5%
ZTSZoetis27.5%
MTDMettler-Toledo International21.9%
ILMNIllumina18.4%
GEHCGE HealthCare Technologies9.3%
ONCBeOne Medicines10.7%
IDXXIDEXX Laboratories25.0%
WATWaters3.6%
Peer median14.5%

Where Royalty Pharma ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.